Active Surveillance Project Research Articles

Cohort event monitoring of safety of COVID-19 vaccines: the Italian experience of the “ilmiovaccinoCOVID19 collaborating group”

Introduction: In 2021, the European Medicines Agency supported the “Covid Vaccine Monitor (CVM),” an active surveillance project spanning 13 European countries aimed at monitoring the safety of COVID-19 vaccines in general and special populations (i.e., pregnant/breastfeeding women, children/adolescents, immunocompromised people, and people with a history of allergies or previous SARS-CoV-2 infection). Italy participated in this project as a large multidisciplinary network called the “ilmiovaccinoCOVID19 collaborating group.”Methods: The study aimed to describe the experience of the Italian network “ilmiovaccinoCOVID19 collaborating group” in the CVM context from June 2021 to February 2023. Comprising about 30 partners, the network aimed to facilitate vaccinee recruitment. Participants completed baseline and follow-up questionnaires within 48 h from vaccination over a 6-month period. Analyses focused on those who completed both the baseline and the first follow-up questionnaire (Q1), exploring temporal trends, vaccination campaign correlation, and loss to follow-up. Characteristics of recruited vaccinees and vaccinee-reported adverse drug reactions (ADRs) were compared with passive surveillance data in Italy.Results: From June 2021 to November 2022, 22,384,663 first doses and 38,207,452 booster doses of COVID-19 vaccines were administered in Italy. Simultaneously, the study enrolled 1,229 and 2,707 participants for the first and booster doses, respectively. Of these, 829 and 1,879 vaccinees, respectively, completed both baseline and at least Q1 and were included in the analyses, with a significant proportion of them (57.8%/34.3%) belonging to special cohorts. Most vaccinees included in the analyses were women. Comirnaty® (69%) and Spikevax® (29%) were the most frequently administered vaccines. ADR rates following Comirnaty® and Spikevax® were higher after the second dose, particularly following Spikevax®. Serious ADRs were infrequent. Differences were observed in ADR characteristics between CVM and Italian passive surveillance.Conclusion: This study confirmed the favorable safety profile of COVID-19 vaccines, with findings consistent with pivotal clinical trials of COVID-19 vaccines, although different proportions of serious ADRs compared to spontaneous reporting were observed. Continuous evaluation through cohort event monitoring studies provides real-time insights crucial for regulatory responses. Strengthening infrastructure and implementing early monitoring strategies are essential to enhance vaccine safety assessment and prepare for future pandemics.

Abstract B050: Human interpretation of 3D histopathology image datasets of whole prostate biopsies reveals more cribriform pattern (Gleason pattern 4) carcinoma than is seen in standard 2D histology images

Abstract Background: Prostate biopsies of patients suspected of having cancer are taken to identify and grade the cancer, if present. These biopsies are currently diagnosed based on thin (up to 4 micron thick) sections of 1 mm thick biopsies. Consequently, only a minor portion of the tissue is examined (a set of 4 micron thick sections from 1 mm thick biopsies is less than 1% of the tissue). We developed a microscope and process that can nondestructively generate 3D image datasets of whole biopsies, allowing complete examination of the tissue specimen as a series of virtual sections. We hypothesize that clinically important grades of the cancer can be found by examining all levels of the biopsies. Methods: This study is based on 161 biopsies of low to intermediate grade cancer taken from radical prostatectomies that had been collected for an active surveillance project of the Canary Foundation. The formalin-fixed biopsy tissue was deparaffinized, stained with fluorescence analogues of hematoxylin and eosin (H&E), optically cleared, imaged in 3D, and false colored to resemble H&E stains. Two sets of images were created. One set was based on current practice – sections at 3 levels with 20 micron spacing between levels. The second set fully imaged the biopsy in 3D with at least 500 virtual levels per biopsy (at a spacing of ~1 micron per level). The images were acquired using a custom-developed 3D open-top light-sheet (OTLS) microscope and were diagnosed and graded by two pathologists using a web-based viewing platform. Results: Biopsies that had been fully imaged in 3D had more foci of intermediate risk grade cancer (Grade Group/GG 2 to 3) than biopsies that had been imaged based on current standard of practice. With 3D pathology, 13% of the biopsies had the cribriform variant of Gleason pattern 4 cancer when 2D pathology did not, while only 4.3% of the biopsies had cribriform carcinoma in 2D but not in 3D. However, when looking at overall GG, a similar number of biopsies were upgraded from low-grade (GG = 1) to higher-grade cancer (GG > 1) when comparing 3D to 2D images, and vice versa. Conclusion: Due to thorough sampling of tissue, viewing 3D datasets of whole prostate biopsies reveals more biopsies with cribriform pattern carcinoma than is seen in standard 2D pathology images. However, the grade of the PCa in the overall set of 161 biopsies is not changed. This is most likely due to poorly formed glands (Gleason pattern 4) being “downgraded” to well formed glands (Gleason pattern 3) when viewed as 3D vs 2D images. Based on these findings, more research is warranted to examine whether human interpretation of 3D pathology datasets can better predict patient prognosis and, thus, lead to treatment more appropriate for the grade of the cancer in a patient than is provided by standard 2D histopathology. Citation Format: Lawrence D. True, Peter A. Humphrey, Vanessa Roybal, Suet-Ling Sarah Chow, Weisi Xie, Jonathan T. C. Liu. Human interpretation of 3D histopathology image datasets of whole prostate biopsies reveals more cribriform pattern (Gleason pattern 4) carcinoma than is seen in standard 2D histology images [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr B050.

SC222 - The update from bladder cancer italian active surveillance (BIAS) project for low-grade bladder tumors: long-term oncological outcomes of patients under active surveillance

SC222 - The update from bladder cancer italian active surveillance (BIAS) project for low-grade bladder tumors: long-term oncological outcomes of patients under active surveillance

MP54-13 THE UPDATE FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT FOR LOW-GRADE BLADDER TUMORS: LONG-TERM ONCOLOGICAL OUTCOMES OF PATIENTS UNDER ACTIVE SURVEILLANCE

MP54-13 THE UPDATE FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT FOR LOW-GRADE BLADDER TUMORS: LONG-TERM ONCOLOGICAL OUTCOMES OF PATIENTS UNDER ACTIVE SURVEILLANCE

Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.

BackgroundThe optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium's global AS database.Materials and MethodsIntensity of surveillance biopsy schedules was categorized according to centers’ protocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4, and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity.ResultsOut of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51–1.83; p < 0.001), while risk of upgrading did not differ (HR = 0.96; 95% CI = 0.84–1.10).ConclusionResults suggest more frequent biopsy schedules may deter some men from continuing AS despite no evidence of grade progression.

A0226 - The update from Bladder Cancer Italian Active Surveillance (BIAS) project for low-grade bladder tumors: Long-term oncological outcomes of patients under active surveillance

A0226 - The update from Bladder Cancer Italian Active Surveillance (BIAS) project for low-grade bladder tumors: Long-term oncological outcomes of patients under active surveillance

SC12 - Active surveillance in low-grade non-muscle-invasive bladder cancers. Results after 8 years of bladder cancer Italian Active Surveillance (BIAS) project

SC12 - Active surveillance in low-grade non-muscle-invasive bladder cancers. Results after 8 years of bladder cancer Italian Active Surveillance (BIAS) project

PD63-05 ONCOLOGICAL LONG-TERM OUTCOMES OF PATIENTS UNDER ACTIVE SURVEILLANCE FOR LOW-GRADE BLADDER TUMORS: AN UPDATE FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT

You have accessJournal of UrologyBladder Cancer: Non-invasive III (PD63)1 Sep 2021PD63-05 ONCOLOGICAL LONG-TERM OUTCOMES OF PATIENTS UNDER ACTIVE SURVEILLANCE FOR LOW-GRADE BLADDER TUMORS: AN UPDATE FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT Roberto Contieri, Nicola Frego, Marco Paciotti, Pietro Diana, Pier Paolo Avolio, Alessandro Uleri, Davide Maffei, Vittorio Fasulo, Massimo Lazzeri, Alberto Saita, Nicolò Maria Buffi, Giovanni Lughezzani, Paolo Casale, Giorgio Guazzoni, and Rodolfo Hurle Roberto ContieriRoberto Contieri More articles by this author , Nicola FregoNicola Frego More articles by this author , Marco PaciottiMarco Paciotti More articles by this author , Pietro DianaPietro Diana More articles by this author , Pier Paolo AvolioPier Paolo Avolio More articles by this author , Alessandro UleriAlessandro Uleri More articles by this author , Davide MaffeiDavide Maffei More articles by this author , Vittorio FasuloVittorio Fasulo More articles by this author , Massimo LazzeriMassimo Lazzeri More articles by this author , Alberto SaitaAlberto Saita More articles by this author , Nicolò Maria BuffiNicolò Maria Buffi More articles by this author , Giovanni LughezzaniGiovanni Lughezzani More articles by this author , Paolo CasalePaolo Casale More articles by this author , Giorgio GuazzoniGiorgio Guazzoni More articles by this author , and Rodolfo HurleRodolfo Hurle More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002107.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Natural history of Low-risk Non-Muscle-Invasive Bladder Cancers (NMIBCs) is characterized by a high recurrence rate and a very low progression rate. Active Surveillance (AS) has emerged as a validated therapeutic approach in Low-risk NMIBCs patients in order to avoid or, at least, postpone invasive surgical treatment. The aim of this study was to confirm the oncological long-term safety of AS and to present the last updated results from Bladder Cancer Italian Active Surveillance (BIAS) project. METHODS: This prospective observational cohort study started in January 2013 and it included 214 patients with pathologically confirmed NMIBC experiencing recurrence during the follow-ups and accepted AS monitoring. AS monitoring was based on the Urine Cytology (UC) and flexible in-office cystoscopy every 3 months for the first year, and every 6 months afterwards. The inclusion criteria was: history of Low Grade NMIBC (G1–2) pTa/ pT1a; number of tumors: between one to five; size of the single tumor: <1 cm; absence of gross hematuria and negative urine cytology for high-grade carcinoma. Failure was defined as reaching the exclusion criteria after being enrolled. RESULTS: The BIAS protocol included 214 patients (251 AS events), with a median age of 72 years (IQR 66-78). Most patients were male (175/214, 81.7%) and 109 (50.9%) patients were active or former smokers. After the first TUR 55 patients had received intravesical therapy with mitomycin C and 20 with BCG. The median follow-up was 38.8 months (IQR 28.6-55.5) while the median time on AS was 13 months (IQR 7-24). Pathological characteristics before entry into AS were: 196 TaG1-G2 and 17 T1aG1G2. The median interval between the primary diagnosis and AS enrolment was 36 months (IQR 16-62.5). Of 251 AS events, 130 (51.8%) were estimated to require surgical treatment, because of: increases in the size of tumors (n=51); increases in the number of tumors (n=34); increase in both the number and size (n=29); positive UC (n=11) and gross hematuria (n=3); in two cases surgery was performed due to patients request. An upstage from LG tumor to HG/CIS was found in 14 cases (11.6%), while pT2 tumor was found in 1 case (0.07%). In 25 cases (19,2%) pathological specimens from AS failures didn't show tumor. 114 patients are still under observation. CONCLUSIONS: Our study findings confirmed the oncological safety of AS which might be a reasonable strategy to avoid unnecessary TURBT in patients with small LG pTa/pT1a recurrent BC. Additional studies are required to avoid unnecessary TURB. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1139-e1140 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Roberto Contieri More articles by this author Nicola Frego More articles by this author Marco Paciotti More articles by this author Pietro Diana More articles by this author Pier Paolo Avolio More articles by this author Alessandro Uleri More articles by this author Davide Maffei More articles by this author Vittorio Fasulo More articles by this author Massimo Lazzeri More articles by this author Alberto Saita More articles by this author Nicolò Maria Buffi More articles by this author Giovanni Lughezzani More articles by this author Paolo Casale More articles by this author Giorgio Guazzoni More articles by this author Rodolfo Hurle More articles by this author Expand All Advertisement Loading ...

Insights on the Impact of External and Internal Boosting on Varicella-Zoster Virus Reactivation Based on Evidence From the First Decade of the United States Universal Varicella Vaccination Program.

Since the licensure of the varicella vaccine in the United States in 1995 and the implementation of the universal varicella vaccination program, varicella infection rates, and associated morbidity and mortality rates have decreased. However, controversy exists over whether universal vaccination has resulted in an increased incidence of herpes zoster (HZ). In 1965, Dr. Hope-Simpson hypothesized that exogenous exposures to the wild-type varicella-zoster virus (wt-VZV) provide immune boosts that inhibit HZ; therefore, reducing the amount of circulating wt-VZV may have the negative effect of increasing the incidence of HZ. A historical review of data from the Centers for Disease Control and Prevention-sponsored Antelope Valley Varicella Active Surveillance Project, along with other studies, is provided to investigate the exogenous boosting hypothesis in the first decade post-vaccine licensure. These data indicated that adoption of universal varicella vaccination led to (1) significant HZ incidence rate increases among children, adolescents, and adults with a history of wild-type varicella and (2) decline in varicella vaccine efficacy after the initial post-licensure period. These effects were likely due to reduced exogenous exposures from children shedding wt-VZV. Appropriate methodologies for ongoing research are also discussed, both in studies during the first decade post-licensure and more recent work.

P0751 - Oncological long-term outcomes of patients under active surveillance for low-grade bladder tumors: An update from the Bladder Cancer Italian Active Surveillance (BIAS) project

P0751 - Oncological long-term outcomes of patients under active surveillance for low-grade bladder tumors: An update from the Bladder Cancer Italian Active Surveillance (BIAS) project

Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non–muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience

Active surveillance (AS) has been proposed as an alternative to transurethral resection (TUR) in selected patients with recurrent low-risk non–muscle-invasive bladder cancer (NMIBC). Here we report long-term results for patients on AS and investigate features associated with AS failure. Cases with recurrence after diagnosis of low-grade (LG) pTa/pT1a NMIBC were enrolled in the Bladder Italian Active Surveillance (BIAS) project. Over 251 AS events, we observed 130 failures (51.8%). In these patients, final pathology showed 25 benign lesions (19.2%) and 92 LG Ta (70.7%), 12 high-grade Ta/T1 (9.2%), and one T2 (0.7%) tumor. The treatment-free probability at 12, 18, 24, and 36 mo was 59.7%, 54.5%, 46.3%, and 40.4%, respectively. We identified 95 patients (37.8%) who remained on AS for >18 mo. A multivariable Cox regression model confirmed that patients with a history of multiple TURs (hazard ratio [HR] 1.59, 95% confidence interval [CI] 1.01–2.51) and those with more than one lesion at AS entry (HR 1.63, 95% CI 1.05–2.54) were significantly more likely to experience AS failure. Our results confirm that well-selected patients with NMIBC can safely remain on AS for a long period of time. Multiple TURs and multiple lesions at AS enrollment are associated with a higher risk of AS failure. Patient summaryActive surveillance has been proposed as an alternative to surgery for patients with recurrent low-risk superficial bladder cancer. Our report confirms that well-selected patients can safely avoid or postpone surgery.

SC282 - Oncological long-term safety and pathological outcome evaluation for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: result from Bladder Cancer Italian Active Surveillance (BIAS) project

SC282 - Oncological long-term safety and pathological outcome evaluation for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: result from Bladder Cancer Italian Active Surveillance (BIAS) project

AEFIs active surveillance projects as vaccinovigilance traineeship: Puglia (Italy) experience

Abstract Surveillance of Adverse Events Following Immunization (AEFIs) is a crucial part of vaccination strategies because the most important concern of “No-vax group” is the safety of vaccination. According to UE laws, in Italy a passive surveillance system of AEFIs is established by law and managed by National Drug Authority (AIFA) and Regional Health Governments. The performance of surveillance system is different in the 21 Italian Regions and in some Region, such as Puglia, the AEFIs reporting rate has been, for several years, lower than National figure. The implementation of AEFIs active surveillance projects could increase the performance of AEFIs surveillance system, also after the end of the project. In Puglia, since 2017, May to 2018, November, an active surveillance of AEFIs has been established, focused on MMRV vaccine. In this study, we analysed the AEFIs general picture in Puglia in 2016 and 2019, before and after active surveillance project. The source of data is the AIFA database; data were reported as number of AEFI and rate for Puglia population (reporting rate RR). The AEFIs were classified as serious, not serious and unclassifiable and causality assessment was performed according to WHO recommendations. The number of AEFIs detected by the passive surveillance system is 91 for 2016 (RR 2,2 per 100.000 people), and 168 for 2019 (RR 4,2 per 100.000 people). The percentage of serious AEFIs was 23.1% (21/91) in 2016 and 31% (52/168) in 2019 and unclassifiable AEFIs were 22% (20/91) in 2016 and 0 in 2019. The percentage of serious AEFIs for which the result of causality assessment was “consistent” is 23,8% (5/21) in 2016 and 55,8% (29/52) in 2019. The experience of AEFIs active surveillance project increase the performance of AEFIs surveillance system. From 2016 (pre-project time) to 2019 (post-project time) the number of AEFIs detected was doubled, the number of unclassifiable AEFIs (proxy of poor reliability of the system) was reduced to zero. Key messages AEFIs passive surveillance system could be affected by underreporting and lack of quality. The AEFIs active surveillance project are an important occasion of traineeship for vaccinovigilance system, that could increase the sensibility and the reliability.

771 - Oncological long-term safety and pathological outcome evaluation for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from bladder cancer Italian active surveillance (BIAS) project

771 - Oncological long-term safety and pathological outcome evaluation for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from bladder cancer Italian active surveillance (BIAS) project

657 - Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in Active Surveillance (AS) patients with recurrent Non-Muscle Invasive Bladder Cancer (NMIBC): Results from the Bladder Cancer Italian Active Surveillance (BIAS) project

657 - Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in Active Surveillance (AS) patients with recurrent Non-Muscle Invasive Bladder Cancer (NMIBC): Results from the Bladder Cancer Italian Active Surveillance (BIAS) project

Practice and thinking of acute respiratory infection surveillance for the response of emerging respiratory diseases in Shanghai

Shanghai Municipal Center for Disease Control and Prevention has implemented an active comprehensive surveillance project of acute respiratory infections in adults in Shanghai, including influenza like illness (ILI) and severe acute respiratory infection (SARI). By testing and identifying a variety of respiratory pathogens, it was found that influenza viruses were the main pathogens in 172 ILI cases in 2019. The positive rates of influenza A (H1N1) pdm09 virus, influenza A (H3N2) virus and influenza B virus Victoria lineage were 30.81%, 14.53% and 30.55%, respectively. The positive detection of influenza A (H1N1) pdm09 virus peaked in the first quarter. The positive rate of enterovirus/human rhinovirus was 6.40%, with a positive detection peak in the third quarter, while the positive rate of adenovirus was 4.65% with a positive detection peak in the second quarter of the year. Two human coronavirus (HCoV)-OC43 positive samples, 1 HCoV-HKU1 positive sample and 1 HCoV-NL63 positive sample were detected, respectively, and no HCoV-229E positive sample was detected. The detection rate of Staphylococcus aureus was 17.44%, and the detection rate of Klebsiellapneumoniae was 9.88%. Influenza viruses were also the main pathogens in 1 447 SARI cases. The positive rates of influenza A (H1N1) pdm09 virus, influenza A (H3N2) virus and influenza B virus Victoria lineage were 5.46%, 1.73% and 0.30%, respectively. The positive detection of influenza A (H1N1) pdm09 virus (17.50%) peaked in the first quarter. The total positive detection rate of enterovirus/human rhinovirus was 2.97%, the positive detection peaked in the first quarter. The positive rate of Mycoplasma pneumoniae was 3.25% and the positive rate of Legionella was 1.04%. 5 HCoV-229E positive samples, 10 HCoV-OC43 positive samples, 7 HCoV-HKU1 positive samples and 6 HCoV-NL63 positive samples were detected. Eight strains of Staphylococcus aureus, 4 strains of Pseudomonas aeruginosa and 3 strains of Klebsiella pneumoniae were detected after cultures. By implementing the active surveillance, we not only detected a case of human infection with avian influenza A(H7N9) virus in time, but also preliminary understood the pathogenic spectrum characteristics and seasonality of ILI and SARI in Shanghai. In recent years, the surveillance methods have been continuously improved and the number of sentinel hospitals has increased gradually. In particular, for the response to COVID-19, the Surveillance Information Reporting System of Acute Respiratory Infection based on HIS system has been promoted to cover the whole city, which might lay a foundation for the active surveillance and early warning of emerging infectious diseases in the future.

Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project

To investigate the clinical performance of a new mRNA-based urine test, aiming to avoid unnecessary follow-up cystoscopy in patients under active surveillance (AS) for recurrent NMIBC. This is a prospective cohort study enrolling patients with history of low-grade (LG) NMIBC, who developed a recurrence during the follow-up and underwent AS. Their urinary samples were analyzed by Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA). The primary endpoint was to investigate if Xpert BC Monitor could avoid unnecessary cystoscopy during the follow-up period. Its sensitivity, specificity, PPVs and NPVs were calculated. A cutoff of 0.4 "linear discriminant analysis" (LDA) was optimized for the AS setting. The cohort consisted of 106 patients with a mean age of 72 ± 9.52 and a median follow-up from AS start of 8.8 (range 0-56.5) months. No statistically significant difference was found for the mean age, smoker status, lesion size, and number of lesions with a cutoff of 0.4. Of 106 patients, 22 (20.8%) were deemed to require treatment because of cystoscopic changes in size and/or number of lesions during the follow-up period. Using a cutoff value of < 0.4, 34 (33.7%) cystoscopies could be avoided due to low LDA value, missing 2/22 (9%) failures, none with high-grade (HG) NMIBC. Further research on larger population remains mandatory before its clinical use. Xpert BC Monitor seems to be a reliable assay, which might avoid unnecessary cystoscopies without missing HG NMIBC when its cutoff is optimized for the AS setting.

Update of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from bladder cancer italian active surveillance (BIAS) project

Update of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from bladder cancer italian active surveillance (BIAS) project

Clinical performance of xpert bladder cancer monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle invasive bladder cancer (NMIBC): Results from the bladder cancer italian active surveillance (BIAS) project

Clinical performance of xpert bladder cancer monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle invasive bladder cancer (NMIBC): Results from the bladder cancer italian active surveillance (BIAS) project

702 - Up-date of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from Bladder Cancer Italian Active Surveillance (BIAS) project

702 - Up-date of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from Bladder Cancer Italian Active Surveillance (BIAS) project